1 completed, 1 not yet recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
Follow LY-2157299: new trials by email Literature Review of LY-2157299 trials Research Report on LY-2157299
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling Galunisertib + Nerandomilast Combination - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 / Phase 3 | Not yet recruiting | Gipfel Life Sciences GmbH | 60 | 2026-06-30 | 2026-01-07 |
| A Study of Galunisertib in Participants With Myelodysplastic Syndromes Galunisertib, Placebo - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 43 | 2014-03-01 | 2019-09-11 |
Amyotrophic Lateral Sclerosis (1) · Myelodysplastic Syndromes (1)
Eli Lilly and Company (1) · Gipfel Life Sciences GmbH (1)
Germany (1) · Italy (1) · Spain (1)